Intuitive Surgical Inc.

Johnson & Johnson experienced a mid-July stock pullback of approximately 2% following earnings results, but analysts view this as a buying opportunity. The company reported strong Q2 results with $25.31B in revenue (up 6.8% YOY), beat EPS expectations at $2.90, and raised full-year guidance. With a diversified portfolio, robust pipeline, upcoming...

Intuitive Surgical's stock has declined 26% over the past 12 months due to lower-than-expected margins from its da Vinci 5 launch and tariff-related cost increases. However, Goldman Sachs analyst David Roman maintains a 'buy' rating with a $558 price target (47% upside), arguing the company's long-term prospects remain strong. The da Vinci 5's ad...

The AI in orthopedic surgery market is experiencing remarkable growth with a projected CAGR of 27.2% through 2030. Key drivers include rising musculoskeletal disorders, AI-assisted surgical planning, robotic surgical systems integration, and enhanced implant placement precision. North America leads the market, while Asia-Pacific and Europe show g...

Intuitive Surgical maintains a dominant position in the robotic surgery market with its Da Vinci system, which benefits from strong competitive moats including surgeon training, high switching costs, and deep operating room integration. The company's recurring revenue model—driven primarily by accessories, instruments, and service contracts rat...

Intuitive Surgical, maker of the da Vinci surgical robot, has surged over 400% in the past decade despite currently trading 30% below all-time highs. The company's real growth driver is recurring revenue from services, instruments, and accessories rather than robot sales. With a current P/E of 49x (below its 5-year average of 69x), aggressive gro...